BioWorld

Dec. 2, 2005

View Archived Issues

XenoPort Partners Asian Rights To Lead Product With Astellas

XenoPort Inc. could receive more than $85 million after agreeing to out-license Asian rights to its lead product candidate, XP13512, to Astellas Pharma Inc. (BioWorld Today) Read More

Rigel's Rhinitis Drug Misses Primary Endpoint In Phase II

Read More

Crucell Acquiring Berna Biotech In US$449M All-Share Takeover

Read More

Lexicon, Genentech Sign $25M Drug Discovery Deal Expansion

Read More

Other News To Note

Read More